What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Axel Grothey mainly focuses on Internal medicine, Colorectal cancer, Oncology, Oxaliplatin and Clinical trial.
His research investigates the connection between Internal medicine and topics such as Surgery that intersect with issues in Placebo.
His work carried out in the field of Colorectal cancer brings together such families of science as Survival rate, Gastroenterology, Disease, Proportional hazards model and Bevacizumab.
His Oncology study incorporates themes from Cetuximab, Metastasis, Survival analysis and Hazard ratio.
The study incorporates disciplines such as Calcium and Pharmacology in addition to Oxaliplatin.
The Clinical trial study combines topics in areas such as Meta-analysis, Adjuvant, Randomized controlled trial and Adverse effect.
His most cited work include:
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial (1559 citations)
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer (1308 citations)
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer (961 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Oncology, Colorectal cancer, Oxaliplatin and Clinical trial.
Much of his study explores Internal medicine relationship to Surgery.
His biological study spans a wide range of topics, including Regorafenib, Adverse effect, Adjuvant therapy and Hazard ratio.
He usually deals with Regorafenib and limits it to topics linked to Placebo and Clinical endpoint.
His Colorectal cancer research integrates issues from Metastasis, Fluorouracil and Disease.
The various areas that he examines in his Oxaliplatin study include Gastroenterology, Regimen, Capecitabine and Pharmacology.
He most often published in these fields:
- Internal medicine (72.23%)
- Oncology (62.33%)
- Colorectal cancer (57.67%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (72.23%)
- Colorectal cancer (57.67%)
- Oncology (62.33%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Colorectal cancer, Oncology, Cancer research and Cancer.
All of his Internal medicine and Clinical trial, Oxaliplatin, Regorafenib, Adverse effect and Disease investigations are sub-components of the entire Internal medicine study.
His study in the fields of Cetuximab, Irinotecan, FOLFIRI and KRAS under the domain of Colorectal cancer overlaps with other disciplines such as Text mining.
Many of his research projects under Oncology are closely connected to In patient with In patient, tying the diverse disciplines of science together.
His Cancer research research incorporates themes from Immunohistochemistry, Missense mutation, Pd l1 expression, Microsatellite instability and Gene.
His research in Cancer intersects with topics in Gastroenterology, Overall survival, Cohort and Stage.
Between 2018 and 2021, his most popular works were:
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. (468 citations)
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer (277 citations)
- A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. (236 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Axel Grothey mostly deals with Internal medicine, Colorectal cancer, Oncology, Binimetinib and Encorafenib.
His study in Clinical trial, Cancer, Clinical endpoint, Adverse effect and Regorafenib are all subfields of Internal medicine.
His Colorectal cancer research incorporates elements of Cancer research, Trastuzumab, Survival rate, Mutant and Sunitinib.
His research integrates issues of Stage, KRAS, Chemotherapy and FOLFIRI in his study of Oncology.
His studies deal with areas such as Oxaliplatin and FOLFOX as well as Chemotherapy.
His Binimetinib research is multidisciplinary, incorporating perspectives in Cetuximab, BRAF V600E and Irinotecan.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
